Comparative Pharmacology
Head-to-head clinical analysis: ANDROID 5 versus FORTESTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID 5 versus FORTESTA.
ANDROID 5 vs FORTESTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
Testosterone replacement therapy; testosterone binds to and activates androgen receptors, influencing gene transcription and protein synthesis, leading to the development of male secondary sex characteristics and maintenance of libido, muscle mass, and bone density.
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
Apply one 30 mg metered-dose transdermal system to abdomen or upper arm once daily at the same time each day.
None Documented
None Documented
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
Terminal elimination half-life is 3–4 hours; not clinically significant for once-daily transdermal administration due to sustained absorption.
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
Primarily renal (90% as glucuronide and sulfate conjugates, 10% unchanged); approximately 1% fecal.
Category C
Category C
Androgen
Androgen